CN116077491B - 化合物在制备snx3表达抑制剂中的应用 - Google Patents
化合物在制备snx3表达抑制剂中的应用 Download PDFInfo
- Publication number
- CN116077491B CN116077491B CN202310141309.1A CN202310141309A CN116077491B CN 116077491 B CN116077491 B CN 116077491B CN 202310141309 A CN202310141309 A CN 202310141309A CN 116077491 B CN116077491 B CN 116077491B
- Authority
- CN
- China
- Prior art keywords
- compound
- snx3
- heart failure
- application
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 49
- 102100032829 Sorting nexin-3 Human genes 0.000 title claims abstract description 28
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- 101000708470 Homo sapiens Sorting nexin-3 Proteins 0.000 title claims abstract 5
- 238000002360 preparation method Methods 0.000 title description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract description 9
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 230000026731 phosphorylation Effects 0.000 abstract description 4
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 abstract 1
- 101710103902 Sorting nexin-3 Proteins 0.000 description 23
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- 229910052736 halogen Inorganic materials 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 15
- 150000002431 hydrogen Chemical class 0.000 description 15
- 206010019280 Heart failures Diseases 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 101000743587 Homo sapiens Vacuolar protein sorting-associated protein 26A Proteins 0.000 description 8
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 8
- 102100038398 Vacuolar protein sorting-associated protein 26A Human genes 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000005496 eutectics Effects 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- -1 nitro, hydroxy Chemical group 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102100034273 Annexin A7 Human genes 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920002377 Polythiazyl Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 102000005045 Sorting Nexin Human genes 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108060007774 sorting nexin Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了化合物在制备SNX3表达抑制剂中的应用,该化合物的结构式为
Description
技术领域
本发明涉及化学药物领域,具体涉及一种化合物在制备SNX表达抑制剂中的应用。
背景技术
心力衰竭是由于心肌梗死、心肌病、血流动力学负荷过重、炎症等任何原因引起的心肌损伤,造成心肌结构和功能的变化,最后导致心室泵血或充盈功能低下。慢性心力衰竭是指持续存在的心力衰竭状态,可以稳定、恶化或失代偿。病理性心肌肥大是心力衰竭(heart failure, HF)的过渡阶段,其发病机制复杂,涉及到神经激素、细胞因子、理化刺激、机械压力、活性氧以及炎症反应等多种因素。目前临床上心衰的治疗虽然取得了一定的进展,但其致死率仍然较高。传统的药物治疗“金三角”包括ACEI/ARB、β受体阻滞剂和醛固酮受体拮抗剂,已有大量的临床研究证实它们能够降低慢性心力衰竭患者的病死率和发病率。然而,为了更有效地治疗心衰、逆转心脏重构、提高患者的生存率,新型药物研究也在不断深入探索中。
Lu J, Xu S, Huo Y, et al. Sorting nexin 3 induces heart failure viapromoting retromer-dependent nuclear trafficking of STAT3[J]. Cell Death&Differentiation, 2021, 28(10): 2871-2887.为发明人前期工作,该工作发现在心肌肥大模型下,SNX3介导转录因子STAT3向细胞核方向的转运而发挥抑制心衰作用。
CN110105279A公开了喹啉类化合物,式中,n为0、1或2;R1为氢、C1~4烷基或-CH2COOR5,其中R5为氢或C1~4烷基;
R2、R3、R4各自独立地选自氢、卤素、氰基、硝基、羟基、取代或非取代C1~6烷基、取代或非取代C1~6烷氧基、取代或非取代C1~6环烷基、取代或非取代C1~6环烷氧基、取代或非取代苯基、取代或非取代苯氧基、取代或非取代苄基、取代或非取代苄氧基、取代或非取代苯胺基、2-苯并呋喃、2-噻吩、5-吲哚、3-吡啶或2-呋喃;所述取代是指至少1个位点被以下取代基取代:卤素、氰基、硝基、氨基、羟基、羧基、C1~4烷基、C1~4卤代烷基、C1~4烷氧基、C1~4卤代烷氧基、苯基、苯氧基或甲硫基;或,R2和R3可以成五元或六元环烷基或杂环烷基; R6为氢、卤素、氰基、硝基、羟基、取代或非取代C1~4烷基、取代或非取代C1~4烷氧基。研究表明该喹啉类化合物对STAT3靶点具有显著的特异性抑制作用,且化合物与STAT3靶点结合力高,对STAT3靶点的抑制作用强,选择性好,有望用于制备抗癌药物。Huang Q, Zhong Y, Li B, et al.Structure-based discovery of potent and selective small-moleculeinhibitorstargeting signal transducer and activator of transcription 3(STAT3)[J].European Journal of Medicinal Chemistry, 2021, 221: 113525.也公开了类似的研究结果。未有研究表明该喹啉类化合物可以作为SNX3抑制剂或治疗心力衰竭。
发明内容
本发明的目的在于克服现有技术的至少一个不足,提供一种SNX3抑制剂在制备抗心力衰竭组合物中的应用。
本发明所采取的技术方案是:
本发明的第一个方面,提供:
本发明提供一种化合物及其衍生物在制备抗心力衰竭组合物中的应用,所述化合物的通式如式Ⅰ所示:式(Ⅰ);
式中,R1选自氢、卤素、甲基、甲氧基中的任意一种,R2选自氢、卤素、甲基、甲氧基、苯基中的任意一种,R3选自氢或甲氧基,R4选自苯基或噻吩基;
所述衍生物为所述化合物药学上可接受的盐、溶剂化物、共晶。
在一些实例中,所述心力衰竭为冠心7病、心肌梗死、心绞痛、心肌炎或慢性心力衰竭。
在一些实例中,所述组合物还包括药学上可接受的载体。
在一些实例中,所述药学上可接受的载体包括稀释剂、赋形剂、崩解剂、填充剂、粘合剂、润滑剂、矫味剂、助悬剂、表面活化剂、稳定剂中的至少一种。
在一些实例中,所述组合物的剂型为液体制剂或固体制剂。
在一些实例中,所述液体制剂为糖浆剂、注射溶液、非水溶液、悬浮液或乳剂;所述固体制剂为片剂、锭剂、胶囊、滴丸、丸剂、粒剂或粉剂。
在一些实例中,所述组合物的给药途径包括静脉注射、肌肉注射、皮下注射或口服给药。
在一些实例中,所述化合物的结构式为(即R1和R3为H、R2为OMe、R4为苯基,记为W1122)。
本发明的第二个方面,提供:
化合物及其衍生物在制备SNX3表达抑制剂中的应用,所述化合物的通式如式Ⅰ所示:式(Ⅰ);
式中,R1选自氢、卤素、甲基、甲氧基中的任意一种,R2选自氢、卤素、甲基、甲氧基、苯基中的任意一种,R3选自氢或甲氧基,R4选自苯基或噻吩基;
所述衍生物为所述化合物药学上可接受的盐、溶剂化物、共晶。
在一些实例中,其为实验室用SNX3表达抑制剂,特别不用于任何疾病的治疗。
本发明的第三个方面,提供:
化合物及其衍生物在制备VPS26表达抑制剂中的应用,所述化合物的通式如式Ⅰ所示:式(Ⅰ);
式中,R1选自氢、卤素、甲基、甲氧基中的任意一种,R2选自氢、卤素、甲基、甲氧基、苯基中的任意一种,R3选自氢或甲氧基,R4选自苯基或噻吩基;
所述衍生物为所述化合物药学上可接受的盐、溶剂化物、共晶。
在一些实例中,其为实验室用VPS26表达抑制剂,特别不用于任何疾病的治疗。
本发明的有益效果是:
发明人研究发现式(Ⅰ)所示的化合物,特别是W1122能够在分子水平上,与SNX3蛋白相互作用,抑制SNX3的蛋白表达量,同时也抑制STAT3的磷酸化水平(Y705)。最终,该化合物抑制ISO诱导的慢性心力衰竭,有望靶向慢性心力衰竭复杂的多重发病机制,具有防治多种心脏疾病的应用。
附图说明
图1 是W1122化合物与SNX3蛋白的亲和力图。
图2是W1122化合物具有抑制SNX3蛋白表达的作用图。
图3是W1122化合物具有抑制VPS26蛋白表达的作用图。
图4是W1122化合物抑制STAT3信号通路作用图。
图5为W1122化合物可抑制ISO诱导的原代心肌细胞肥大作用图。
具体实施方式
本发明的第一个方面,提供:
本发明提供一种化合物及其衍生物在制备抗心力衰竭组合物中的应用,所述化合物的通式如式Ⅰ所示:式(Ⅰ);
式中,R1选自氢、卤素、甲基、甲氧基中的任意一种,R2选自氢、卤素、甲基、甲氧基、苯基中的任意一种,R3选自氢或甲氧基,R4选自苯基或噻吩基;
所述衍生物为所述化合物药学上可接受的盐、溶剂化物、共晶。
在一些实例中,所述心力衰竭为冠心7病、心肌梗死、心绞痛、心肌炎或慢性心力衰竭。
在一些实例中,所述组合物还包括药学上可接受的载体。
在一些实例中,所述药学上可接受的载体包括稀释剂、赋形剂、崩解剂、填充剂、粘合剂、润滑剂、矫味剂、助悬剂、表面活化剂、稳定剂中的至少一种。
在一些实例中,所述组合物的剂型为液体制剂或固体制剂。
在一些实例中,所述液体制剂为糖浆剂、注射溶液、非水溶液、悬浮液或乳剂;所述固体制剂为片剂、锭剂、胶囊、滴丸、丸剂、粒剂或粉剂。
在一些实例中,所述组合物的给药途径包括静脉注射、肌肉注射、皮下注射或口服给药。
在一些实例中,所述化合物的结构式为(即R1和R3为H、R2为OMe、R4为苯基,记为W1122)。
本发明的第二个方面,提供:
化合物及其衍生物在制备SNX3抑制剂中的应用,所述化合物的通式如式Ⅰ所示:式(Ⅰ);
式中,R1选自氢、卤素、甲基、甲氧基中的任意一种,R2选自氢、卤素、甲基、甲氧基、苯基中的任意一种,R3选自氢或甲氧基,R4选自苯基或噻吩基;
所述衍生物为所述化合物药学上可接受的盐、溶剂化物、共晶。
在一些实例中,其为实验室用SNX3抑制剂,特别不用于任何疾病的治疗。作为实验室用SNX3抑制剂应用时,用于对SNX3进行抑制,研究SNX3抑制后可以带来何种生物效应。
在一些实例中,所述化合物的结构式为(W1122)。
本发明的第三个方面,提供:
化合物及其衍生物在制备VPS26表达抑制剂中的应用,所述化合物的通式如式Ⅰ所示:式(Ⅰ);
式中,R1选自氢、卤素、甲基、甲氧基中的任意一种,R2选自氢、卤素、甲基、甲氧基、苯基中的任意一种,R3选自氢或甲氧基,R4选自苯基或噻吩基;
所述衍生物为所述化合物药学上可接受的盐、溶剂化物、共晶。
在一些实例中,所述化合物的结构式为(W1122)。
在一些实例中,其为实验室用VPS26表达抑制剂,特别不用于任何疾病的治疗。
SNX3(sorting nexin 3)是SNXs(sorting nexins)家族中结构最简单的亚型,仅包含PX基本结构域,可直接与货物选择复合体VPS26-VPS35结合形成复合物,对货物蛋白的回收和降解进行分类和调节,介导货物蛋白从内体到TGN或细胞质膜的逆向转运,从而避免了被溶酶体降解。本实验室前期工作发现,在心肌肥大模型下,SNX3介导转录因子STAT3向细胞核方向的转运而发挥抑制心衰作用。因此,式Ⅰ所示化合物及其衍生物,特别是W1122及其衍生物有望应用于制备抗心力衰竭组合物。
下面结合实验数据,进一步说明本发明的技术方案。
实施例1:W1122化合物对SNX3的亲和力较强
将蛋白冰上融解后低温超滤,使之不含甘油和咪唑。用PBS缓冲液配成100μg/mL浓度,通过氨基偶联方式锚定到CM5芯片上。W1122溶于经0.22μm滤膜过滤后的PBS缓冲液中,配制成20μM母液,用含有0.1%DMSO的SPR缓冲液倍半稀释,得到10μM,5μM,2.5μM,1.25μM,0.625μM和0.3125μM的稀释液。将不同浓度的化合物由低到高依次通过芯片,获得响应信号。通过Biacore Insight评价软件计算动力学和亲和度,确定结合亲和度(KD)。
实验结果如图1所示,从实验结果可以看出,W1122化合物与SNX3的KD值为2.6μM,说明W1122化合物对SNX3的亲和力较强。
实施例2:W1122化合物对SNX3蛋白、VPS26蛋白和STAT3磷酸化程度的影响
细胞经不同处理后,吸去培养基,加入含有蛋白酶抑制剂和磷酸酶抑制剂的细胞裂解液 RIPA裂解细胞,在水平摇床上摇晃裂解15min后,将裂解液在12000rpm,4℃条件下离心15min,取上清定量,加入5×loading buffer,煮沸变性。然后用聚丙烯酰胺凝胶SDS-PAGE电泳分离蛋白样品,再转移至PVDF膜上,经5%脱脂牛奶封闭1h后,分别用SNX3、VPS26、pY705-STAT3、α-tubulin的一抗在4℃下孵育过夜,再分别用兔二抗、鼠二抗室温孵育1h,最后用Tanon显影仪检测蛋白的表达水平。
实验结果如图2~图4所示,图2显示W1122化合物会抑制SNX3蛋白表达;图3显示W1122化合物会抑制VPS26蛋白表达;图4显示W1122化合物抑制STAT3(Y705)磷酸化程度。
实施例3:W1122化合物可抑制ISO诱导的原代心肌细胞表面积的增大
在48孔板中接种原代心肌细胞,给予相应处理结束后,弃去培养基。PBS洗涤后,加入提前放至室温的4 %多聚甲醛固定15 - 20 min。之后弃去多聚甲醛,室温下空气干燥。加入0.3 % Triton在室温下避光透膜10 min并用PBS轻洗3次。加入0.1 % 罗丹明-鬼笔环肽(可用PBS按1:1000的比例进行稀释)室温避光孵育30 min(30 min后可在细胞成像系统下观察着色情况)后,用PBS轻洗3次。加入0.1 % DAPI室温避光孵育1-5 min,用PBS洗去浮色。使用细胞成像进行观察细胞大小。图(5)显示,W1122化合物可抑制ISO诱导的原代心肌细胞表面积的增大。
以上是对本发明所作的进一步详细说明,不可视为对本发明的具体实施的局限。对于本发明所属技术领域的普通技术人员来说,在不脱离本发明构思的简单推演或替换,都在本发明的保护范围之内。
Claims (1)
1.化合物及其衍生物在制备体外实验室用SNX3表达抑制剂中的应用,其特征在于,所述化合物的结构式为,所述衍生物为所述化合物药学上可接受的盐。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310141309.1A CN116077491B (zh) | 2023-02-21 | 2023-02-21 | 化合物在制备snx3表达抑制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310141309.1A CN116077491B (zh) | 2023-02-21 | 2023-02-21 | 化合物在制备snx3表达抑制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116077491A CN116077491A (zh) | 2023-05-09 |
CN116077491B true CN116077491B (zh) | 2024-02-02 |
Family
ID=86186948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310141309.1A Active CN116077491B (zh) | 2023-02-21 | 2023-02-21 | 化合物在制备snx3表达抑制剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116077491B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107502610A (zh) * | 2017-09-13 | 2017-12-22 | 中国科学院深圳先进技术研究院 | 一种靶向STAT3信号通路miRNA及其制备方法和应用 |
CN110105279A (zh) * | 2019-04-15 | 2019-08-09 | 中山大学 | 一种喹啉类stat3特异性抑制剂及其制备方法和应用 |
CN110981868A (zh) * | 2019-11-05 | 2020-04-10 | 中山大学 | 咪唑并吡啶类化合物、包含该化合物的药物组合物及其制备方法和用途 |
-
2023
- 2023-02-21 CN CN202310141309.1A patent/CN116077491B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107502610A (zh) * | 2017-09-13 | 2017-12-22 | 中国科学院深圳先进技术研究院 | 一种靶向STAT3信号通路miRNA及其制备方法和应用 |
CN110105279A (zh) * | 2019-04-15 | 2019-08-09 | 中山大学 | 一种喹啉类stat3特异性抑制剂及其制备方法和应用 |
CN110981868A (zh) * | 2019-11-05 | 2020-04-10 | 中山大学 | 咪唑并吡啶类化合物、包含该化合物的药物组合物及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
Sorting nexin 3 induces heart failure via promoting retromer-dependent nuclear trafficking of STAT3;Jing Lu等;《Cell Death Differ》;第28卷(第10期);2871-2887 * |
Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3);Qiuyao Huang;《Eur J Med Chem》;第221卷;1-25 * |
Also Published As
Publication number | Publication date |
---|---|
CN116077491A (zh) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101687883B (zh) | 囊性纤维化跨膜传导调节因子的调节剂 | |
CN101715450B (zh) | 作为cftr调控剂的氮杂吲哚衍生物 | |
CN102245573B (zh) | 作为cftr调节剂的杂芳基衍生物 | |
TWI607753B (zh) | 1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之新穎酸加成鹽 | |
BR112021010871A2 (pt) | Composto agonista do receptor thrb e método de preparação e uso do mesmo | |
CN101925603A (zh) | 囊性纤维化跨膜通道调节因子的调节剂 | |
CN101675928A (zh) | 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑 | |
TWI718113B (zh) | 吡啶甲醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
BG65544B1 (bg) | Фармацевтичен състав с подобрена разтворимост и орална абсорбция, съдържащ бензамидно производно | |
JP2000510866A (ja) | Tnfとpde―ivのインヒビターとしてのキノリンスルホンアミド | |
EP1426046A1 (en) | Novel use of tricyclic compound | |
US7893108B2 (en) | Antiviral methods and compositions | |
KR960009570B1 (ko) | 이미다졸린 유도체 및 그의 제조방법 | |
CN105693624A (zh) | 马西替坦晶体及其制备方法、其药物组合物和用途 | |
CN107151240A (zh) | 一类多取代喹诺酮类化合物及其制备方法和用途 | |
US6673819B2 (en) | Compounds useful as antibacterial agents | |
CN116077491B (zh) | 化合物在制备snx3表达抑制剂中的应用 | |
BG104105A (bg) | Алатрофлоксацинови парентерални състави | |
JP2020529988A (ja) | 医学的障害の予防および治療のための化合物およびその使用 | |
CN106892920B (zh) | 苦豆碱衍生物、其制备方法及用途 | |
JP2002504925A (ja) | Pde ivおよび/又はtnfインヒビターとしてのキノリン誘導体 | |
CN111961043A (zh) | 乙酰唑胺衍生物及其制备方法和在制备治疗冠心病药物中的应用 | |
JPH06506192A (ja) | 阻害剤 | |
JP2021528451A (ja) | 二環式コア部分を有する新規lxrモジュレーター | |
KR20180020223A (ko) | 중수소화된 티에노피페리딘 유도체, 제조방법 및 그 응용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |